John Hussman's HALO Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 52,500 shares of Halozyme Therapeutics, Inc. (HALO) worth $3.53 M, representing 0.85% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 15 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 31,500 shares. Largest reduction occurred in Q3 2025, reducing 52,500 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +21,000 | Add 66.67% | 52,500 | $67.30 |
| Q3 2025 | -52,500 | Reduce 62.50% | 31,500 | $73.34 |
| Q2 2025 | +10,500 | Add 14.29% | 84,000 | $52.02 |
| Q4 2024 | +31,500 | Add 75.00% | 73,500 | $47.81 |
| Q2 2024 | +10,500 | Add 33.33% | 42,000 | $52.36 |
| Q3 2023 | -15,000 | Reduce 32.26% | 31,500 | $38.20 |
| Q1 2023 | +21,700 | Add 87.50% | 46,500 | $38.19 |
| Q4 2022 | -6,200 | Reduce 20.00% | 24,800 | $56.90 |
| Q3 2022 | +21,700 | Add 233.33% | 31,000 | $39.55 |
| Q2 2022 | +9,300 | New Buy | 9,300 | $43.98 |
John Hussman's Halozyme Therapeutics Investment FAQs
John Hussman first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2022, acquiring 9,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Halozyme Therapeutics, Inc. (HALO) for 15 quarters since Q2 2022.
John Hussman's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2024, adding 73,500 shares worth $3.51 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 52,500 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $3.53 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.85% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Halozyme Therapeutics, Inc. (HALO) was 84,000 shares, as reported at the end of Q2 2025.